Tempest Therapeutics

Contributing Author

Recent Articles by Tempest Therapeutics

Aug-13	Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update TPST TPST -13.25% GlobeNewswire
Jul-21	Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T TPST GlobeNewswire
Jul-15	Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 TPST +9.13% GlobeNewswire
Jun-04	Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors TPST GlobeNewswire
May-29	Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds TPST -11.56% GlobeNewswire
May-14	Tempest Reports First Quarter 2026 Financial Results and Provides Business Update TPST +13.59% TPST -12.44% GlobeNewswire
May-06	Tempest Presents Clinical Update at ISCT 2026 Annual Meeting TPST -6.05% GlobeNewswire
Apr-29	Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting TPST GlobeNewswire
Apr-22	Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T TPST GlobeNewswire
Apr-14	Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts TPST +5.14% GlobeNewswire
Mar-30	Tempest Reports Year End 2025 Financial Results and Provides Business Update TPST -12.14% GlobeNewswire
Mar-23	Tempest Therapeutics Announces Up To $6 Million Private Placement TPST -19.65% GlobeNewswire
Mar-11	Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 TPST GlobeNewswire
Feb-25	Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 TPST -6.43% GlobeNewswire
Feb-11	Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets TPST GlobeNewswire
Feb-04	Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets TPST TPST -6.30% GlobeNewswire
Jan-20	Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders TPST -5.15% GlobeNewswire
Nov-26	Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST GlobeNewswire
Nov-25	Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST -23.26% GlobeNewswire
Nov-19	Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 TPST -48.59% GlobeNewswire
Nov-05	Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update TPST +9.10% GlobeNewswire
Aug-11	Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update TPST +8.83% TPST +9.99% GlobeNewswire
Jun-30	Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China TPST GlobeNewswire
Jun-11	Tempest Announces $4.6 Million Registered Direct Offering of Common Stock TPST -15.88% GlobeNewswire
Jun-05	Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC TPST +15.16% GlobeNewswire
May-13	Tempest Reports First Quarter 2025 Financial Results and Provides Business Update TPST GlobeNewswire

Tempest Therapeutics

Recent Articles by Tempest Therapeutics

Upgrade your Finviz experience